Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for the link, SG44. So, it appears that there will be an Omnibus Hearing on Tuesday, and the Governmental Bar Date is set the day before my open sell orders expire on July 2. I don't want to see those orders expire.
I really don't know what that means, and I would much rather see those actions mooted by whatever course of action management might be implementing. But I will say that I continue to sense, everyday, that management is working with Sanofi on their spin-off, and that we could be looking at a partnership with Novavax in association with the Sanofi spin-off.
one of the main reasons companies and individuals hide their assets in swiss banks and cayman islands is not to hide ill gotten gains or hide money and not pay taxes,
the main reason people hide their assets under various corporations is to prevent easy access to funds from fake gov't fines and gov't confiscation and fake lawsuits and fake creditor claims. fake creditors who claim you owe them money or millions can be used as means of 'extortion' like guilliiani where some women claim he sexually harassed and judge gives here 100 million settlement and he was forced to declare bankruptcy.? he should object to such obscene and unfair fines order by anyone. the punishment doesn't fit the 'alledged' harm. it's like getting a 1 million dollar fine for speeding ticket or lying on your loan application due to technicalities. or lyaing about your net worth on some loan application when it's the job of the bank claims to be 'defrauded' when most loans are given based on credit checks etc. and it's the bank's problem if borrowere defaults on loan, not the gov't problem.
in bankruptcy court, the court ASSUMES all the FAKE creditor claims are true if the debtor doesn't OBJECT to the claims.
okay. and the debtor doesn't seem to object to the fake creditor claims because it wants to get sued and auction off the ip assets for free since the debtor is also the only bidder and owns Taran.
if feel you've been ripped as an investor, don't waste time with complaining to SEC which normally just sends a warning letter to the corporate head office which is now just an post office in a shared office and only receiving mail. if the company is dissolved case closed and SEC won't waste time with it, the company is dead if dissolved and legally you cannot put a dead man in prison.
alternative is criminal case
that is where the case goes to criminal charges by FBI or FTC.
if they cannot get an CRIMINAL conviction due to lack of evidence or nobody bother filing a criminal charge for larceny or fraud. and conviction, people go to prison. for like 4 years like Trump for lying on his loan application. or insider trading and front running, market manipulation etc which were made FELONY crimes by the gov't
then next step is CIVIl COURT. usually people found guilty of wrong doings or FRAUD don't go to prison and just pay a fine to the complainant, it's like divorce settlement in people's court. it's not a violent crime like armed robbery. etc
I certainly believe in Lenzilumab, we are both in heavy agreement with everything you shared.
My post is purely based on the asset disclosure that was filed, which of course does not include Lenzilumab as it has been sold to Taran. If management truly is doing something clever to help out shareholders that would be incredible, and I hope it is the case. My current viewpoint, despite being unfortunate, is only based on what I can read in the mass amount of filings I've reviewed.
I've still got my fingers crossed. I'm fairly certain we'll find out rather soon.
In any event, here is the link I promised to share where all dockets can be pulled: https://dm.epiq11.com/case/humanigen/info
I'm fully aware that the SEC has sealed the records in their case against Dale's entities, and I hope he prevailed in the Court of Appeals. I mean, really, management spelled out their share structure, to include the use of company insiders as nominee account holders, in an SEC filing. I knew as soon as I read the filing what they were doing, and why they were doing it. It was because management knew that the SEC would not protect them, and they had to have a plan to defend themselves, which they did very well.
"Based on the asset disclosure it doesn't appear there is nearly enough $ to reach us."
I think lenzilumab may prove to be the biggest blockbuster drug ever to hit the market. That is not a new conclusion, nor is it based on news that management has kept under wraps. Lenzilumab's astounding safety and efficacy was duly reported in the topline data of their LIVE-AIR trial, which showed a Hazard Ratio of 1.54, which was a 54% improvement over standard of care.
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Reports-Positive-Phase-3-Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventila-O9C2T.pdf
Just based on the release of the topline data, with the 54% improvement over placebo and standard of care, the market reacted so favorably that I was able to sell shares for as much as $27.78 and $29.07 on March 29, 2021.
"Highlights over the past year include:
Lenzilumab in COVID-19 patients
Completed the LIVE-AIR study, which showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for invasive mechanical ventilation compared with patients receiving standard of care and placebo.
Positive results of the LIVE-AIR study were published in The Lancet Respiratory Medicine, https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext. The Lancet publication concluded that lenzilumab treatment of patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile comparable to placebo..."
https://www.sec.gov/Archives/edgar/data/1293310/000121465922003320/ex99_1.htm
Here again, we see management reporting the peer-reviewed results published in Lancet. But in addition to the topline data, and the Lancet peer-review, the company reported the publication of a second peer-review in Thorax. This was on using CRP as a biomarker, and it showed that the early use of lenz in hospitalized and hypoxic covid pneumonia patients showed that "... baseline CRP <150 mg/L (HR: 2.54; 95% CI 1.46 to 4.41; p=0.0009)."
https://thorax.bmj.com/content/78/6/606
Personally, I think our market has greatly expanded to include treatment of non-hospitalized covid pneumonia patients. I base this on the Thorax peer review, which concluded:
"Exploratory analysis for the effect of lenzilumab on SWOV was conducted by the CRP baseline quartile. Response to lenzilumab was observed in the first through third quartiles of baseline CRP with the greatest lenzilumab treatment effect observed in the first quartile (CRP <41 mg/L; HR: 8.20; 95% CI 1.74 to 38.69; p=0.0079)." (Info is in paragraph just above Table 3).
We're seeing reports now that Pfizer and Moderna provide 70 - 80% of the FDA's operating revenue, and that NIH and NIAID scientists are receiving royalties from these manufacturers. Here is four year old data from the FDA acknowledging this practice.
"About 55 percent, or $3.2 billion, of FDA’s budget
is provided by federal budget authorization. The
remaining 45 percent, or $2.7 billion, is paid for
by industry user fees."
https://www.fda.gov/media/143704/download#:~:text=authorization%20funds%20about%2062%20percent,%40fda.hhs.gov.
That's why lenz, with an 8-fold improvement in treatment outcomes, when administered early to patients with CRP levels <41 mg/L, can't get regulatory approval, and consequently, millions of covid patients have, or will, suffer preventable deaths. This collusion and graft is what happens when executive agency bureaucrats have "discretionary authority," which I think should be rescinded.
Lenz was intended as a cancer drug before covid came along, and an effective CMML cancer drug is what lenz has proven to be.
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
— Humanigen, Inc. (@humanigen) June 9, 2023
Full Story: https://t.co/mXv7opGRkr
@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Medical
The identities of the owners of taran and hgenq is UNKNOWN and secret hidden in layers and layers of different bank accounts and beneficiaries like the ADR based in cayman islands. the papers or beneficiaries are secret too and not disclosed. nobody really knows who actually owns Taran or hgenq as the current 4 'employees' are just hired hands and front people. or the frontman of this operation. I know one guy who runs 10 stocks okay. or a few entities control the entire market.
What YOU don't understand is the design of the company's share structure, where company insiders were merely the nominee share holders. They held shares for the beneficial owner. Transactions reflecting buys and sells amongst Dale's entities, were actually just reflecting the transfer of shares between the entities.
what don't you understand, the company or entity who loan the shares loan the shares to another entity they own to short. in other words, the company loan the shares to themselves. like Taran also owns and controls hgenq the controlling shareholder...what you don't understand. why you think Taran got or won the ip assets of lenzi which say could be worth millions or billions. technically, Taran bought all the ip assets for FREE. as the book value says all of hgenq assets include LENZI was worth ZERO value. so they paid nothing for it technically speaking
The company provided the 'locates,' meaning they agreed to loan the shares. They have a right to recall those loaned shares. Brokers will be forced to buy-in their short sellers.
Because authorized shares was 250 million shares,
they could easily raise additional equity via share dilution or issuing more shares to raise capital to continue operations instead of going bankrupt. the lawsuits were fake and the company wanted to get sued so it declare chapter 11. and make equity worthless after selling over 100 million in equity in 2021 and 2022. after bankruptcy, the guy still owns the ip assets and investors who bought the shares get nothing and shares worthless. it's classic stock scam. that is a common theme in many companies. but its so obvious now. too obvious.
authorized shares is : 250,000,000 shares
outstanding shares: 119,080,135
shares held at DTC Depository Trust Corporation for trading: 36,460,494
shares still short: 38,497 as of may 31,2024 still short and not covered which is ridiculous.
makes the data unreliable and ask yourself --who would still be short in a bankrupt stock now?
DTC shares are shares sold to customers via brokerages
Where does Cowtown get the loan shares and recall?
unless he has other information that I don't have. there is no share recall. it could shares shorted naked and not in publicly available information. or swaps where or OTC counter contracts between parties. that the company has with the market makers of this ticker. either cowtown jay is dilusional about this ticker or has another thing coming.
retail accounts cannot short 100 million shares of many stocks as there is no shares to short or limited. and you have to pay your brokerage fees to short. lots of stock had no shares to short. to short shares, the buyer would have to borrow money or the shares are on margin for the broker to lend it out and shorter has to pay a short fee which discourages shorting for retail accounts as a result only professional or market makers can short naked as they don't have to pay shorting fees. so any cash you get from shorting you cannot collect interest on it.
that is why you still see millions of shares STILL Short or own loan and still not covered. the entity who still owns this stock or owns 110 million lent the shares to himself to short. once they shorted all their shares, they want to bankrupt the company and make it worthless and go bankrupt and don't have to cover and still own the company even though it was sold.
here is a stock tip:
the shares shorted WAS shorted by the owners of the company via another entity as short trade.
they sold all their shares SHORT and still own the shares. so they never have to cover yet still control 110 million shares and own the company even though they sold the company via shorting in 2021 with raising new equity. you think they would have covered right? it's one of the deep secrets of the market. or wall street and it involves co operation from the market maker of the exchange and market marker when it was still trading in nasdaq.
To me, part of the reason for investing here has always been a stock play, such they executed previously DBA Kalobios. Does this sound familiar?
"KaloBios has been surging since Shkreli bought a 70% stake in the company earlier in November, rescuing it from insolvency. The company had announced just a week earlier that it was winding down operations because it was running out of cash while developing two potential cancer drugs."
https://www.marketwatch.com/story/kalobios-short-sellers-facing-squeeze-as-ceo-shkreli-says-will-no-longer-lend-stock-2015-11-27
alternate source:
https://moxreports.com/kbio-infinity-squeeze/
I have seen no reason to think that the company will not achieve certain strategic objectives, associated with Australian regulatory approval to treat CMML, perhaps with the addition of Filip Dubovsky to work with our new entity and with the Sanofi spin-off. I also believe Humanigen may control ~90% of their Outstanding Shares.
But to be sure, we appear to be in a precarious situation. However, I just don't believe that we are. I will believe that until management tells us differently.
I do hope you are correct. From my extremely limited knowledge of chapter 11 proceedings, my understanding is that the treatment section for classifications is all but guaranteed. While I see the sections you quoted as well, I believe that's only if those of us that fall in class 5 receive a payout after the liquidation of the assets. Based on the asset disclosure it doesn't appear there is nearly enough $ to reach us. With that said, I could be very incorrect.
Tomorrow back at my desk I'd be happy to share the file cache link on the epiq website which contains all files since January.
Thank you, SorcererGuru44.
I see that the last sentence on page 38/70 still contains the following.
"Pursuant to the Combined Plan and Disclosure Statement, the Liquidating Trustee, in its sole discretion, may establish the Existing Equity Interests Record Date should there be a Distribution to Holders of Allowed Existing Equity Interests."
https://document.epiq11.com/document/getdocumentbycode?docId=4343564&projectCode=HUM&source=dm
The section for Treatment of Existing Equity Holders that you quoted also notes, a few paragraphs after the information you quoted, the following.
"Allowance: Existing Equity Interests held by Holders thereof as
of the Existing Equity Interests Distribution Record Date (which
such date may be established by the Liquidating Trustee in its sole
and absolute discretion) shall be Allowed Existing Equity
Interests under the Combined Plan and Disclosure Statement (as
reflected by DTC and/or the Debtor’s official register of holders
of common stock)."
I suspect there is going to be a significant difference in the number of shares reported by the DTC, versus the number of shares reported by the company's Transfer Agent.
We'll see how things transpire. It could get interesting if the company requests to have their shares in certificate form. However, you did source the material I was waiting for, and I very much appreciate your post.
Contrary to what I've been reading about myself, I am not paid to post. I've said that before, but it evidently bears repeating. I've also said repeatedly that I am retied, and living on a fixed income, and sometimes unexpected repairs, etc., have to be put off. So at the earliest possible time, if good news is on our horizon, I want to hear it. My open sell orders will expire in about two weeks. As I look at the pieces that have to be put into play for our success, I'm seeing what think are key components coming together. I know that lenz will be hugely successful, and I want to see existing equity holders, including management, receive the reward we deserve.
Once again, thank you for sourcing the important information you provided. Well done!
Hi Jay,
I certainly can. All relevant documents are on the epiq website. The one I'm mentioning in my previous post is here I believe on page 45 (don't quote me on the specific page number though):
https://document.epiq11.com/document/getdocumentbycode?docId=4343564&projectCode=HUM&source=dm
I did reach out to epiq council via email, and they confirmed class 5 is indeed us as shareholders.
Hello and welcome to the room, SorcererGuru44. Can you link a source for material you quoted? I'm not seeing a new filing. Do you have a Pacer account?
While I have a shred of hope remaining, it is awfully hard to ignore the language used in the combined disclosure plan related to shareholders. Humanigen is dissolving and stockholders will not receive anything.
"Class 5 – Existing Equity Interests
Classification: Class 5 consists of all Existing Equity Interests.
Treatment: On the Effective Date, Existing Equity Interests shall be cancelled and will be of no further force or effect. Following payment in full of all other Allowed Claims, except to the extent that a Holder of an Allowed Existing Equity Interest agrees to less favorable treatment, in exchange for full and final satisfaction, settlement, and release of each Allowed Existing Equity Interest, each Holder of such Allowed Existing Equity Interest shall receive its Pro Rata share of the Liquidating Trust Proceeds."
Just the rampant in your face fraud, where elon just got approved by board of directors for his 50 billion dollar salary, he doesn't even work at Tesla, elon was just the investment banker of tesla, or frontman. he just embezzled 50 billion for tesla for his bosses. you actually t hink tesla deserves 50 billion cash that he wants? that is how corrupt wall street and corporate america, the voting was rigged. nobody in their right mind would think elon should get 50 billion in salary for doing nothing. and is not stock options, he wants cash because if he was to get paid in stock, he have to sell in the open market to get the cash and it would crash the stock.
It's worthless until it's not. Hoping for a miracle with the gamble I took on the stock. If not, then oh well and onto the next trade.
"...the question is why is cowtown who probably paid to post every day here?"
You have no clue how important lenz will be to the world.
all penny stocks and otc markets are dead too...only handful of stocks still get interest the market has no breadth as they say.
Hindenburg Omen
the market is high on super light volume on hot air. technically speaking
this is a classic stock scam to ripoff investors with fake news, fake bankruptcy fraud, this company if the assets had value,,,they would not buy it for nothing in stock bid, those assets are worth millions if it has value. and can sell for license or fda approval..why you think they got investors to pay $10/share for it in 2021 and raised over 100 million in ipo equity or new equity.
As for why the one guy who s till has not sold his worthless 100 milloin shares, its so he can control the company. normally these 4 employees and directors would be fired already.
because it is worthless. with the information we have now unless ou have insider information.
why would i want to save you or want to help you? the question is why is cowtown who probably paid to post every day here? 99% of the stocks at otc are scams, and everybody knows it. hgenq was not sold as a scam in 2021 and sold 100 million in equity..now at otc if you bought under 10 cents, you know the shares are worthless like 99% of the stocks in the exchange.
maybe you can pump and dump the stock and SEC would not care either. it's an illiquid stock no sellers and no buyers.
Here again, I agree with a part of what you say. The SEC gave the crooks the playground to rip off the public. But I disagree that there are no share loans. You know that can't be right, because you recognize (from somewhere - me?) that a single entity owns 110M shares. So if Humanigen controls about 90% of their OS, then management aren't the crooks, and my only question is whether Taran, or the Humanigen/Taran entity, will benefit by the forced covering, whether prompted by a merger, or by a recall of the loaned shares, or both.
I think the SEC tried to squash this situation, especially if the NIH owns so much of Moderna. If so, will this bankruptcy judge allow Humanigen's assets to be transferred to the US Treasury? Or will he order those funds to be returned to Humanigen and the injured shareholders? More often than not, judges recognize the discretionary authority of the executive branch agencies. But, in this case, the judge may recognize a conflict of interest in the agencies, and disallow the discretionary authority to convert our funds to the Treasury Department.
The Question I ask is why do this? If our shares are worthless then why is this individual so concerned about our shares? LOL
All the reason I need to stay grounded and will not sell anything.
Thank god another savior decided to start another new account today and share all this unknown information.
only privilleged and special accounts get to sell NAKED shares and privilleged accounts known as market makers don't have to pay fees for shorting shares either like retail accounts and can short any shares especially 'worhtless shares' at any amount of money SEC gave these crooks the playground to rip off the public.
probably some 'fake' press release with fake news.
fake share buybacks there is no share buybacks you actually these guys would actually buy back shares? and there is no share loans, those naked shares that they never have to cover.
"Currently, my primary hope is to see Cameron's leadership in action. Do you have any insights or observations in this regard?"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173637404
Stay tuned. I think he has set the stage.
I agree that the shares are, "... useless and worthless with the information that is available today..." and that there is a single entity, "...who still owns 110 million shares." The meaning of that entire dynamic will change with a Press Release, which I am eagerly anticipating. I think you picked a bad time to come back.
That annoying busybody is back again and again.
before crypto coins, tax havens like cayman islands and switzerland banks, etc were used for money laundering. and the penny stock shell companies they were used mainly for money laundering. there is no demand for tax havens in cayman island or these island as there is no privacy in all banks who has to use USD or swift banking.
anyways this ticker useless and worthless with the information that is available today. and reason the one guy who still owns 110 million shares is he controls the bankruptcy filing and needs the bankrupcy to be concluded so he can walk free from this 100 million dollar robbery. and hide the assets in some trust fund.
as for now with the information that is available. the ticker hgenq is worthless and has no value and soon to be deregistered and deslisted too. it's only good as a shell company and may be dissolved and shares cancelled. good for money laundering or shell company other than no equity value.
And reason the Trust is created and liquidation is so all the assets and claims of hgen is in some trust with no liens on it. so if you buy STOLEN assets from a trust, people cannot sue the trust
these people are high class theives and crooks...it's rich theives theives wearing $10,000 suits.
a theif is still a theif.
what is the point of creating a trust for and pay someone thousands per year to 'administer' it and you need to file a form to get to the assets. you trust these theives and crooks to honor anything?
there is NO HONOR among thieves.
chapter 11 and chapter 7 cases are administrative process no need to waste time with 300 documents. 100% of the time equity gets zero. and shares are deregistered and company dies. A corporation has same rights as man. A dead corporation or dead man cannot repay debts. The Trust is useless. what for. the ip that Taran bought or stole for free has a LIEN on it and under common law is disputed Assets or HOT Assets or stolen assets. anyone who buys would be buying or STOLEN assets or cursed property. that is the law.
this is bankruptcy fraud case and should be in criminal court not bankruptcy court.
if you feel you've been ripped don't waste time with SEC, they been paid off to ignore people who think they are ripped off.
as for the .047/share they get nothing and wasted their time probably paid $1000 bucks to apply to the 'shareholder lawsuit'
management wanted to get sued and wanted to go bankrupt so it can STEAL and buy the lenzi patent for free. okay
those FAKE creditors who want 40 million in 'disputed' should get nothing and should be countersued for harasseement with fake lawsuits but management made up the fake lawsuits. from chime an patheon.
"... the potential of a Record Date being declared, exactly for a Distribution to shareholders (which I think could be for shares of Taran, equal to the number of our Humanigen shares)."
I don't see why a distribution to existing equity holders should not be declared. The Unsecured Creditors are looking forward to the amended plan which will increase the number and amount of payments they will receive. These Milestone Payments are based on regulatory approval which seems likely to first come from Australia as the result of our PREACH-M trial for CMML.
With the progress management has made, I truly don't see how existing equity holders could fail to be rewarded.
I didn't try to attend the Novavax shareholders' meeting this morning, since I'm not a shareholder. So I'll have to wait 24 hours to see if relevant news was reported.
"NOVAVAX, INC.'s meeting has concluded. A replay will be available in 24 hours at: www.virtualshareholdermeeting.com/NVAX2024"
https://central.virtualshareholdermeeting.com/vsm/web?pvskey=NVAX2024
The agenda appeared pretty mundane. But they did make note of a Proxy Statement relevant to stockholders as of May 3rd.
https://novavax.widen.net/s/zdd7jdmbbj/2024-proxy-statement
So, no news from Novavax until after our Hearing today.
DTG, the only thing that I can't figure out is why the reorganization bankruptcy was changed to a liquidating bankruptcy, but one in which a distribution may be made to existing equity holders. I can only assume that we have one too many pieces to the puzzle, and that we'll end up with shares in Taran, as the licensor of lenz to Sanofi and Novavax, and that we may merge with Novavax, and perhaps become a subsidiary of Sanofi. That would at least explain why we don't need the Humanigen shell.
Maybe, and hopefully, we'll get news tomorrow.
I hope once we see these game changing announcements come along, that they will include the CDNO stock. It would be incredible to see us brought back from the dead even though I remain skeptical. That would be Awesome!!! I am still rooting for you Jay in that you end up being right about everything.
Leukemia patient, 17 year old Dazelle Peters, who had also suffered Acute Graft versus Host Disease, died Monday after being denied lung transplants because she was not vaccinated.
Dazelle was the embodiment of the patient populations in the RATinG and PREACH-M clinical trials sponsored by our IMPACT and SAHMRI partners. Lenzilumab may have saved the life of this beautiful young lady.
As JFK said, a rising tide lifts all boats. This might explain an increased interest in Humanigen.
As Zack's Equity Research noted, "Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks Equity Research
Mon, Jun 10, 2024...
Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately...Shares of this vaccine maker have returned +104.6% over the past month versus the Zacks S&P 500 composite's +3.3% change...For the current quarter, Novavax is expected to post earnings of $1.13 per share, indicating a change of +94.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +241.6% over the last 30 days...The consensus earnings estimate of $0.37 for the current fiscal year indicates a year-over-year change of +106.8%. This estimate has changed +144.5% over the last 30 days."
https://finance.yahoo.com/news/investors-heavily-search-novavax-inc-130016966.html
Novavax further provides FLS cautions as follows. "... (Our) and Sanofi’s ability to successfully implement its partnership, including the ability to transition key processes and effect technology transfers, Novavax’s and Sanofi’s ability to successfully develop or commercialize any vaccines or vaccine candidates, our ability to successfully and timely manufacture, distribute, or market our updated COVID-19 vaccine including as a single dose vial or pre-filled product presentation for the 2024-2025 vaccination season, our plans to sell our COVID-19 vaccine for the 2024-2025 vaccination season under Emergency Use Authorization; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for our product candidates, including our updated COVID-19 vaccine in time for the 2024-2025 vaccination season in the U.S. and in foreign jurisdictions to meet APA commitments or for future COVID-19 variant strain changes, our COVID-19-Influenza combination vaccine candidate and our stand-alone influenza vaccine candidate; manufacturing, distribution or export delays or challenges; our substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling and PCI Pharma Services for finishing our COVID-19 vaccine and the impact of any delays or disruptions in their operations on the delivery of customer orders..."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465924068875/tm2416490d1_8k.htm
I didn't know that Novavax had a business relationship with PCI Pharma, but I knew of Humanigen's relationship with PCI. I also see Cenexi being mentioned in other posts, and I know we also had a business relationship with them. The closer we get to Novavax's stockholder meeting tomorrow, which is also when we will hear about the bankruptcy court's decision regarding our expanded and increased Asset Purchase Agreement, and a possible distribution to existing equity holders of Humanigen shares, the more optimistic I become.
I hope to see two game-changing announcements from Humanigen this week, or in the near term. One announcement may be in regards to further utilizing our notice of patent allowance for the enhancement of CAR-T immunotherapy.
https://www.pennystockdream.com/blog/hgen-up-3217-after-hours-after-receiving-notice-of-allowance-for-patent-application
I actually think that Gracell and Mayo Clinic are already benefitting from this CAR-T enhancement, and I hope that Sanofi will bring this to market not only for their platforms, but for our partner, the South Australian Health and Medical Research Institute ("SAHMRI"), also.
""Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development."
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx
The second announcement I'm looking forward to will be after the Novavax stockholder meeting on the 13th, which coincides with our bankruptcy hearing detailing the expanded Milestone Event triggers and payments.
Chris Cuomo interviews Dr. Robert Redfield on the many ways Long Covid presents. The gist of the discussion is summarized in the last 8 minutes of the video. I share this video because I think we are only beginning to understand just how much we really don't understand, if that makes sense to you. This lack of understanding frustrates me to no end. The frustration started in 2020 as my wife's condition deteriorated, and there was no no appreciation of how lenz could improve her brain functioning. And the frustration continues as I look at the swelling in my right foot and calf, despite taking an anti-coagulant and blood thinner, which I think lenz could improve by reducing the inflammation.
Man, I'm looking forward to getting lenz into the hands of the medical community, where the real discovery can begin.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
7
|
Posts (Total)
|
43266
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |